{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:49:04Z","timestamp":1773820144302,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>External beam radiotherapy (RT) is a leading first-line therapy for prostate cancer (PCa), and, in recent years, significant advances have been accomplished. However, RT resistance can arise and result in long-term recurrence or disease progression in the worst-case scenario. Thus, making crucial the discovery of new targets for PCa radiosensitization. Herein, we generated a radioresistant PCa cell line, and found p53 to be highly expressed in radioresistant PCa cells, as well as in PCa patients with recurrent\/disease progression submitted to RT. Mechanism dissection revealed that RT could promote p53 expression via epigenetic modulation. Specifically, a decrease of H3K27me3 occupancy at <jats:italic>TP53<\/jats:italic> gene promoter, due to increased KDM6B activity, was observed in radioresistant PCa cells. Furthermore, p53 is essential for efficient DNA damage signaling response and cell recovery upon stress induction by prolonged fractionated irradiation. Remarkably, KDM6B inhibition by GSK-J4 significantly decreased p53 expression, consequently attenuating the radioresistant phenotype of PCa cells and hampering in vivo 3D tumor formation. Overall, this work contributes to improve the understanding of p53 as a mediator of signaling transduction in DNA damage repair, as well as the impact of epigenetic targeting for PCa radiosensitization.<\/jats:p>","DOI":"10.1038\/s41392-023-01639-6","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:02:00Z","timestamp":1697414520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling"],"prefix":"10.1038","volume":"8","author":[{"given":"Catarina","family":"Macedo-Silva","sequence":"first","affiliation":[]},{"given":"Vera","family":"Miranda-Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Nuno Tiago","family":"Tavares","sequence":"additional","affiliation":[]},{"given":"Daniela","family":"Barros-Silva","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Lencart","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Lobo","sequence":"additional","affiliation":[]},{"given":"\u00c2ngelo","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Margareta P.","family":"Correia","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7312-5387","authenticated-orcid":false,"given":"Lucia","family":"Altucci","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"1639_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","volume":"5","author":"RX Huang","year":"2020","unstructured":"Huang, R. X. & Zhou, P. K. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct. Target Ther. 5, 60 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"1639_CR2","doi-asserted-by":"crossref","unstructured":"Mar\u00e9chal, A. & Zou, L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb. Perspect. Biol. 5, a012716 (2013).","DOI":"10.1101\/cshperspect.a012716"},{"key":"1639_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","volume":"10","author":"M Macheret","year":"2015","unstructured":"Macheret, M. & Halazonetis, T. D. DNA replication stress as a hallmark of cancer. Annu. Rev. Pathol. 10, 425\u2013448 (2015).","journal-title":"Annu. Rev. Pathol."},{"key":"1639_CR4","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1158\/1078-0432.CCR-13-3229","volume":"21","author":"MA Morgan","year":"2015","unstructured":"Morgan, M. A. & Lawrence, T. S. Molecular pathways: overcoming radiation resistance by targeting DNA damage response pathways. Clin. Cancer Res. 21, 2898\u20132904 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1639_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2015.2","volume":"16","author":"WP Roos","year":"2016","unstructured":"Roos, W. P., Thomas, A. D. & Kaina, B. DNA damage and the balance between survival and death in cancer biology. Nat. Rev. Cancer 16, 20\u201333 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"1639_CR6","doi-asserted-by":"crossref","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","DOI":"10.3322\/caac.21660"},{"key":"1639_CR7","doi-asserted-by":"crossref","unstructured":"Khuntia, D., Reddy, C. A., Mahadevan, A., Klein, E. A. & Kupelian, P. A. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect? Cancer 100, 1283\u20131292 (2004).","DOI":"10.1002\/cncr.20093"},{"key":"1639_CR8","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1586\/14737140.8.6.967","volume":"8","author":"TJ Fitzgerald","year":"2008","unstructured":"Fitzgerald, T. J. et al. Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention. Expert Rev. Anticancer Ther. 8, 967\u2013974 (2008).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"1639_CR9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","volume":"8","author":"SC Morgan","year":"2018","unstructured":"Morgan, S. C. et al. Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline. Pr. Radiat. Oncol. 8, 354\u2013360 (2018).","journal-title":"Pr. Radiat. Oncol."},{"key":"1639_CR10","first-page":"7190","volume":"63","author":"SL Scott","year":"2003","unstructured":"Scott, S. L., Earle, J. D. & Gumerlock, P. H. Functional p53 increases prostate cancer cell survival after exposure to fractionated doses of ionizing radiation. Cancer Res. 63, 7190\u20137196 (2003).","journal-title":"Cancer Res."},{"key":"1639_CR11","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1089\/ars.2012.4938","volume":"19","author":"D De Zio","year":"2013","unstructured":"De Zio, D., Cianfanelli, V. & Cecconi, F. New insights into the link between DNA damage and apoptosis. Antioxid. Redox Signal. 19, 559\u2013571 (2013).","journal-title":"Antioxid. Redox Signal."},{"key":"1639_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86681-6","volume":"11","author":"S Anbalagan","year":"2021","unstructured":"Anbalagan, S. et al. TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells. Sci. Rep. 11, 7119 (2021).","journal-title":"Sci. Rep."},{"key":"1639_CR13","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1038\/onc.2009.509","volume":"29","author":"E Soto-Reyes","year":"2010","unstructured":"Soto-Reyes, E. & Recillas-Targa, F. Epigenetic regulation of the human p53 gene promoter by the CTCF transcription factor in transformed cell lines. Oncogene 29, 2217\u20132227 (2010).","journal-title":"Oncogene"},{"key":"1639_CR14","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/sj.onc.1210787","volume":"27","author":"LJ Warnock","year":"2008","unstructured":"Warnock, L. J., Adamson, R., Lynch, C. J. & Milner, J. Crosstalk between site-specific modifications on p53 and histone H3. Oncogene 27, 1639\u20131644 (2008).","journal-title":"Oncogene"},{"key":"1639_CR15","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1093\/nar\/gkn550","volume":"36","author":"A Kinner","year":"2008","unstructured":"Kinner, A., Wu, W., Staudt, C. & Iliakis, G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 36, 5678\u20135694 (2008).","journal-title":"Nucleic Acids Res."},{"key":"1639_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0092-8674(00)80416-X","volume":"91","author":"SY Shieh","year":"1997","unstructured":"Shieh, S. Y., Ikeda, M., Taya, Y. & Prives, C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325\u2013334 (1997).","journal-title":"Cell"},{"key":"1639_CR17","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.4161\/epi.6.9.16683","volume":"6","author":"R Salda\u00f1a-Meyer","year":"2011","unstructured":"Salda\u00f1a-Meyer, R. & Recillas-Targa, F. Transcriptional and epigenetic regulation of the p53 tumor suppressor gene. Epigenetics 6, 1068\u20131077 (2011).","journal-title":"Epigenetics"},{"key":"1639_CR18","doi-asserted-by":"publisher","first-page":"e96545","DOI":"10.1371\/journal.pone.0096545","volume":"9","author":"K Williams","year":"2014","unstructured":"Williams, K. et al. The histone lysine demethylase JMJD3\/KDM6B is recruited to p53 bound promoters and enhancer elements in a p53 dependent manner. PLoS ONE 9, e96545 (2014).","journal-title":"PLoS ONE"},{"key":"1639_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3892\/ol.2021.12922","volume":"22","author":"X Kong","year":"2021","unstructured":"Kong, X., Yu, D., Wang, Z. & Li, S. Relationship between p53 status and the bioeffect of ionizing radiation. Oncol. Lett. 22, 661 (2021).","journal-title":"Oncol. Lett."},{"key":"1639_CR20","doi-asserted-by":"crossref","unstructured":"Zdrowowicz, M., Datta, M., Rych\u0142owski, M. & Rak, J. Radiosensitization of PC3 prostate cancer cells by 5-thiocyanato-2\u2019-deoxyuridine. Cancers 14, 2035 (2022).","DOI":"10.3390\/cancers14082035"},{"key":"1639_CR21","first-page":"235","volume":"113","author":"D B\u00f6hmer","year":"2016","unstructured":"B\u00f6hmer, D. et al. Radiotherapy and hormone treatment in prostate cancer. Dtsch. Arztebl. Int. 113, 235\u2013241 (2016).","journal-title":"Dtsch. Arztebl. Int."},{"key":"1639_CR22","doi-asserted-by":"publisher","first-page":"308","DOI":"10.21037\/tau.2017.12.37","volume":"7","author":"A Dang","year":"2018","unstructured":"Dang, A., Kupelian, P. A., Cao, M., Agazaryan, N. & Kishan, A. U. Image-guided radiotherapy for prostate cancer. Transl. Androl. Urol. 7, 308\u2013320 (2018).","journal-title":"Transl. Androl. Urol."},{"key":"1639_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1615\/CritRevOncog.2018025946","volume":"23","author":"L Chaiswing","year":"2018","unstructured":"Chaiswing, L., Weiss, H. L., Jayswal, R. D., Clair, D. K. S. & Kyprianou, N. Profiles of radioresistance mechanisms in prostate cancer. Crit. Rev. Oncog. 23, 39\u201367 (2018).","journal-title":"Crit. Rev. Oncog."},{"key":"1639_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01111-8","volume":"13","author":"C Macedo-Silva","year":"2021","unstructured":"Macedo-Silva, C. et al. Epigenetic mechanisms underlying prostate cancer radioresistance. Clin. Epigenet. 13, 125 (2021).","journal-title":"Clin. Epigenet."},{"key":"1639_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41418-018-0246-9","volume":"26","author":"F Mantovani","year":"2019","unstructured":"Mantovani, F., Collavin, L. & Del Sal, G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 26, 199\u2013212 (2019).","journal-title":"Cell Death Differ."},{"key":"1639_CR26","doi-asserted-by":"publisher","first-page":"a001081","DOI":"10.1101\/cshperspect.a001081","volume":"1","author":"LA Donehower","year":"2009","unstructured":"Donehower, L. A. Using mice to examine p53 functions in cancer, aging, and longevity. Cold Spring Harb. Perspect. Biol. 1, a001081 (2009).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1639_CR27","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/pros.23741","volume":"79","author":"D Majera","year":"2019","unstructured":"Majera, D. et al. Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram. Prostate 79, 352\u2013362 (2019).","journal-title":"Prostate"},{"key":"1639_CR28","first-page":"220","volume":"34","author":"D Kutilin","year":"2021","unstructured":"Kutilin, D. Genetic and epigenetic bases of prostate tumor cell radioresistance. Klin. Onkol. 34, 220\u2013234 (2021).","journal-title":"Klin. Onkol."},{"key":"1639_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53799-7","volume":"9","author":"S Inder","year":"2019","unstructured":"Inder, S. et al. Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistance. Sci. Rep. 9, 17325 (2019).","journal-title":"Sci. Rep."},{"key":"1639_CR30","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/0360-3016(96)00134-4","volume":"35","author":"P Stattin","year":"1996","unstructured":"Stattin, P., Damber, J. E., Modig, H. & Bergh, A. Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 35, 885\u2013889 (1996).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1639_CR31","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S0360-3016(02)02781-5","volume":"53","author":"MA Ritter","year":"2002","unstructured":"Ritter, M. A., Gilchrist, K. W., Voytovich, M., Chappell, R. J. & Verhoven, B. M. The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 53, 574\u2013580 (2002).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1639_CR32","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/sj.onc.1204252","volume":"20","author":"WR Taylor","year":"2001","unstructured":"Taylor, W. R. & Stark, G. R. Regulation of the G2\/M transition by p53. Oncogene 20, 1803\u20131815 (2001).","journal-title":"Oncogene"},{"key":"1639_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03279-y","volume":"11","author":"C Macedo-Silva","year":"2020","unstructured":"Macedo-Silva, C. et al. JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma. Cell Death Dis. 11, 1068 (2020).","journal-title":"Cell Death Dis."},{"key":"1639_CR34","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.celrep.2018.09.081","volume":"25","author":"J Bayo","year":"2018","unstructured":"Bayo, J. et al. Jumonji inhibitors overcome radioresistance in cancer through changes in H3K4 methylation at double-strand breaks. Cell Rep. 25, 1040\u20131050.e1045 (2018).","journal-title":"Cell Rep."},{"key":"1639_CR35","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.1158\/1078-0432.CCR-18-3890","volume":"25","author":"H Katagi","year":"2019","unstructured":"Katagi, H. et al. Radiosensitization by histone H3 demethylase inhibition in diffuse intrinsic pontine glioma. Clin. Cancer Res. 25, 5572\u20135583 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1639_CR36","doi-asserted-by":"crossref","unstructured":"Nikolaev, A., Fiveash, J. B. & Yang, E. S. Combined targeting of mutant p53 and Jumonji family histone demethylase augments therapeutic efficacy of radiation in H3K27M DIPG. Int. J. Mol. Sci. 21, 490 (2020).","DOI":"10.3390\/ijms21020490"},{"key":"1639_CR37","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/1878-0261.12909","volume":"15","author":"J Lobo","year":"2021","unstructured":"Lobo, J. et al. Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors. Mol. Oncol. 15, 846\u2013865 (2021).","journal-title":"Mol. Oncol."},{"key":"1639_CR38","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/pros.10291","volume":"57","author":"A van Bokhoven","year":"2003","unstructured":"van Bokhoven, A. et al. Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines. Prostate 57, 226\u2013244 (2003).","journal-title":"Prostate"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01639-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01639-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01639-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T03:02:59Z","timestamp":1700449379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01639-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1639"],"URL":"https:\/\/doi.org\/10.1038\/s41392-023-01639-6","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"assertion":[{"value":"23 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study used PCa biopsy specimens as FFPE tissue samples. For that purpose, this study was approved by the institutional review board (Comiss\u00e3o de \u00c9tica para a Sa\u00fade) of IPO Porto, Portugal (CES-238\/020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"395"}}